Show simple item record

Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation

dc.contributor.authorHofmann-Winkler, Heike
dc.contributor.authorMoerer, Onnen
dc.contributor.authorAlt-Epping, Sabine
dc.contributor.authorBräuer, Anselm
dc.contributor.authorBüttner, Benedikt
dc.contributor.authorMüller, Martin
dc.contributor.authorFricke, Torben
dc.contributor.authorGrundmann, Julian
dc.contributor.authorHarnisch, Lars-Olav
dc.contributor.authorHeise, Daniel
dc.contributor.authorKernchen, Andrea
dc.contributor.authorPressler, Meike
dc.contributor.authorStephani, Caspar
dc.contributor.authorTampe, Björn
dc.contributor.authorKaul, Artur
dc.contributor.authorGärtner, Sabine
dc.contributor.authorKramer, Stefanie
dc.contributor.authorPöhlmann, Stefan
dc.contributor.authorWinkler, Martin Sebastian
dc.date.accessioned2020-11-27T11:23:20Z
dc.date.available2020-11-27T11:23:20Z
dc.date.issued2020de
dc.identifier.urihttp://resolver.sub.uni-goettingen.de/purl?gs-1/17663
dc.description.abstractObjectives: Severe acute respiratory syndrome coronavirus 2 cell entry depends on angiotensin-converting enzyme 2 and transmembrane serine protease 2 and is blocked in cell culture by camostat mesylate, a clinically proven protease inhibitor. Whether camostat mesylate is able to lower disease burden in coronavirus disease 2019 sepsis is currently unknown. Design: Retrospective observational case series. Setting: Patient treated in ICU of University hospital Göttingen, Germany. Patients: Eleven critical ill coronavirus disease 2019 patients with organ failure were treated in ICU. Interventions: Compassionate use of camostat mesylate (six patients, camostat group) or hydroxychloroquine (five patients, hydroxychloroquine group). Measurements and Main Results: Clinical courses were assessed by Sepsis-related Organ Failure Assessment score at days 1, 3, and 8. Further, viral load, oxygenation, and inflammatory markers were determined. Sepsis-related Organ Failure Assessment score was comparable between camostat and hydroxychloroquine groups upon ICU admission. During observation, the Sepsis-related Organ Failure Assessment score decreased in the camostat group but remained elevated in the hydroxychloroquine group. The decline in disease severity in camostat mesylate treated patients was paralleled by a decline in inflammatory markers and improvement of oxygenation. Conclusions: The severity of coronavirus disease 2019 decreased upon camostat mesylate treatment within a period of 8 days and a similar effect was not observed in patients receiving hydroxychloroquine. Camostat mesylate thus warrants further evaluation within randomized clinical trials.de
dc.description.sponsorshipOpen-Access-Publikationsfonds 2020
dc.language.isoengde
dc.rightsopenAccess
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectcamostat mesylate; coronavirus disease 2019; sepsis; Sepsis-related Organ Failure Assessmentde
dc.subject.ddc610
dc.titleCamostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observationde
dc.typejournalArticlede
dc.identifier.doi10.1097/CCE.0000000000000284
dc.type.versionpublishedVersionde
dc.relation.eISSN2639-8028
dc.bibliographicCitation.volume2de
dc.bibliographicCitation.issue11de
dc.bibliographicCitation.firstPage1de
dc.bibliographicCitation.lastPage5de
dc.type.subtypejournalArticle
dc.bibliographicCitation.articlenumbere0284de
dc.description.statuspeerReviewedde
dc.bibliographicCitation.journalCritical Care Explorationsde


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

These documents are avalilable under the license:
openAccess